Patient’s Guide: Helicobacter pylori in Peptic Ulcer Disease

Chapter

Abstract

Helicobacter pylori infection can lead to the occurrence of many diseases of the upper gastrointestinal tract and is one of the most common causes of peptic ulcer disease (PUD). This discovery of H. pylori made possible not only to understand the origin of the disease, but also to use an appropriate treatment and prevent PUD recurrence.

Current guidelines do not recommend an active search for H. pylori infection in an asymptomatic population. Nevertheless, prevention of H. pylori infection is possible and even simple recommendations can minimize the spread of bacteria.

The following section contains information regarding epidemiology, transmission routes, symptoms of infection, and contribution of H. pylori into the development of PUD.

Keywords

Gastric ulcer Helicobacter pylori Nonsteroidal anti-inflammatory drugs Peptic ulcer disease Virulence factors 

Abbreviations

CagA

Cytotoxin-associated gene A

LEV

Levofloxacin

LPS

Lipopolysaccharide

MALT

Mucosa associated lymphoid tissue lymphoma

NSAIDs

Nonsteroidal anti-inflammatory drugs

PCR

Polymerase chain reaction

PPIs

Proton pump inhibitors

PUD

Peptic ulcer disease

RUT

Rapid urease test

SAT

Stool antigen test

UBT

Urea breath test

VacA

Vacuolating cytotoxin A

Notes

Acknowledgments

The work is supported by grants from the Medical University of Lodz (#502-03/1-156-04/502-14-239 to AW, #502-03/1-156-04/502-14-299 to PM, and #503/1-156-04/503-11-001 to JF) and grant from National Science Centre [#UMO-2016/21/N/NZ5/01932 to PM].

References

  1. 1.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;8390:1311–5.CrossRefGoogle Scholar
  2. 2.
    Mégraud F. A humble bacterium sweeps this year’s Nobel Prize. Cell. 2005;123:975–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Qadri Q, Rasool R, Gulzar GM, Naqash S, Shah ZA. H. pylori infection, inflammation and gastric cancer. J Gastrointest Cancer. 2014;45:126–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134:306–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;2:CD003840.Google Scholar
  6. 6.
    Benjamin JB, Jayanthi V, Devaraj H. MUC1 expression and its association with other aetiological factors and localization to mitochondria in preneoplastic and neoplastic gastric tissues. Clin Chim Acta. 2010;411:2067–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology. 2005;128:1579–605.CrossRefPubMedGoogle Scholar
  8. 8.
    Raymond J, Thiberg JM, Chevalier C, Kalach N, Bergeret M, Labigne A, Dauga C. Genetic and transmission analysis of Helicobacter pylori strains within a family. Emerg Infect Dis. 2004;10:1816–21.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kabir S. Detection of Helicobacter pylori DNA in feces and saliva by polymerase chain reaction: a review. Helicobacter. 2004;9:115–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown LM, Thomas TL, Ma JL, Chang YS, You WC, Liu WD, Zhang L, Gail MH. Helicobacter pylori infection in rural China: exposure to domestic animals during childhood and adulthood. Scand J Infect Dis. 2001;33:686–91.CrossRefPubMedGoogle Scholar
  11. 11.
    Smoot DT, Mobley HL, Chippendale GR, Lewison JF, Resau JH. Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect Immun. 1990;58:1992–4.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11:385–99.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cooke CL, Huff JL, Solnick JV. The role of genome diversity and immune evasion in persistent infection with Helicobacter pylori. FEMS Immunol Med Microbiol. 2005;45:11–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Sundrud MS, Torres VJ, Unutmaz D, Cover TL. Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A. 2004;101:7727–32.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med. 1994;120:977–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Hentschel E, Brandstätter G, Dragosics B, Hirschl AM, Nemec H, Schütze K, Taufer M, Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol. 1998;93:1080–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Al Asqah M, Al Hamoudi N, Anil S, Al Jebreen A, Al-Hamoudi WK. Is the presence of Helicobacter pylori in dental plaque of patients with chronic periodontitis a risk factor for gastric infection? Can J Gastroenterol. 2009;23:177–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Patel SK, Mishra GN, Pratap CB, Jain AK, Nath G. Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. Biomed Res Int. 2014;2014:483136.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection- the Maastricht IV/Florence Consensus report. Gut. 2012;61(5):646–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, Altayar O, Limburg PJ, Murad MH, Knawy B. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015;21:1305–14.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Paoluzi OA, Visconti E, Andrei F, Tosti C, Lionetti R, Grasso E, Ranaldi R, Stroppa I, Pallone F. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol. 2010;44:261–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59:1465–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Bago J, Majstorović K, Belosić-Halle Z, Kućisec N, Bakula V, Tomić M, Bago P, Troskot R. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob. 2010;9:13.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Furuta T, Sugimoto M, Codaira C. Comparison of triple rabeprazole/metronidazol/sitafloxacin therapy with triple rabeprazole/amoxicillin/sitafloxacin therapy as the third rescue regimen for eradication of H. pylori. Helicobacter. 2010;14:28.Google Scholar
  28. 28.
    Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3750–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, Hui Y, Chan HL, Chan CS, Hui E, Woo J, Sung JJ. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.CrossRefPubMedGoogle Scholar
  31. 31.
    Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Talley NJ, Vakil N, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100:2324–37.CrossRefPubMedGoogle Scholar
  34. 34.
    Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25.CrossRefPubMedGoogle Scholar
  35. 35.
    Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155–68.CrossRefPubMedGoogle Scholar
  36. 36.
    Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21:10644–53.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97–107.PubMedGoogle Scholar
  38. 38.
    Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–79.CrossRefPubMedGoogle Scholar
  39. 39.
    Rosenstock S, Jørgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut. 2003;52:186–93.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lahner E, Annibale B, Delle FG. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther. 2009;29:379–86.CrossRefPubMedGoogle Scholar
  41. 41.
    Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53:34–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Malfertheiner P. Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease. Gut. 2004;53(2):312–3.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineMedical University of LodzLodzPoland

Personalised recommendations